Patents by Inventor Tobias Erik Allander

Tobias Erik Allander has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
    Patent number: 6747136
    Abstract: The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.
    Type: Grant
    Filed: April 17, 1997
    Date of Patent: June 8, 2004
    Assignee: Karolinska Innovations AB
    Inventors: Mats Axel Atterdag Persson, Tobias Erik Allander
  • Human monoclonal antibodies specific for hepatitis C virus (HCV) E2 antigen
    Patent number: 6538114
    Abstract: The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.
    Type: Grant
    Filed: April 19, 1996
    Date of Patent: March 25, 2003
    Assignee: Karolina Innovations AB
    Inventors: Mats Axel Atterdag Persson, Tobias Erik Allander
  • HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR HEPATITIS C VIRUS (HCV) E2 ANTIGEN
    Publication number: 20020016445
    Abstract: The present invention relates to compositions derived from immunoglobulin molecules specific for the hepatitis C virus (HCV). More particularly, the invention is related to molecules which are capable of specifically binding with HCV E2 antigen. The molecules are useful in specific binding assays, affinity purification schemes and pharmaceutical compositions for the prevention and treatment of HCV infection in mammalian subjects. The invention thus relates to novel human monoclonal antibodies specific for HCV E2 antigen, fragments of such monoclonal antibodies, polypeptides having structure and function substantially homologous to antigen-binding sites obtained from such monoclonal antibodies, nucleic acid molecules encoding those polypeptides, and expression vectors comprising the nucleic acid molecules.
    Type: Application
    Filed: April 17, 1997
    Publication date: February 7, 2002
    Inventors: MATS AXEL ATTERDAG PERSSON, TOBIAS ERIK ALLANDER